An official website of the United States government
September 29, 2026 Edition
News
Antiviral drug did not improve Long COVID symptoms
A clinical trial for Long COVID found that treating patients with a common antiviral drug for up to 25 days did not improve symptoms.
News
tRNA treatment may help restore cystic fibrosis proteins
Lipid nanoparticles delivering engineered transfer RNA restored functional proteins in cell and animal models of cystic fibrosis.
News
Bacterial infection may alter developing gut
C. difficile bacteria caused lasting changes to cells in the intestines of newborn mice.
Displaying 309 - 315 of 912
Avoiding RSV in infancy reduces asthma risk
Infants who avoided infection with respiratory syncytial virus, or RSV, during the first year of life had a 26% lower risk of developing asthma by age 5.
Brain decoder turns a person's brain activity into words
Researchers developed a system that can decode language based on a person's brain activity.
Social safety nets may blunt effects of poverty on children's mental health
Socioeconomic disparities in children's brain development and mental health were lower in states with stronger social safety nets.
Sex disparities after heart attack
Women ages 55 and younger have worse outcomes the year after a heart attack than similarly aged men.
Insomnia drug may lower levels of Alzheimer's proteins
In a small study, a drug called suvorexant that is approved to treat insomnia reduced levels of proteins associated with Alzheimer's disease in cerebrospinal fluid.
Aging melanocyte stem cells and gray hair
The stem cells responsible for hair color switch between stem cell and maturing states, but with age can get stuck and become unable to perform either function.
How boosters produce broad protection against COVID-19
A booster shot targeting the Omicron variant of SARS-CoV-2 produced a broader immune response than one targeting variants more similar to the original strain.